new-view-surgical

New View Surgical is proud to be recognized as one of the Top 10 Companies to Watch in 2023 by Medtech Outlook Magazine

sjohnson@newviewsurg.com (Shane Johnson) — Wed, 22 Feb 2023 16:16:47 GMT

New View Surgical is proud to be recognized as one of the Top 10 Companies to Watch in 2023 by Medtech Outlook Magazine

New View Surgical - Surgical Solutions/Service Company (medicaltechoutlook.com)

New View Surgical Announces First Commercial Case

Tue, 06 Dec 2022 20:26:48 GMT

New View Surgical Announces First Commercial Case of the VisionPort™ System, Performed by David Earle, M.D., F.A.C.S.

First in-human procedure completed using the simplified laparoscopic system

December 06, 2022 11:06 AM Eastern Standard Time

BOSTON--( BUSINESS WIRE )-- New View Surgical , an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today the first-in-human procedure utilizing the VisionPort™ System. The VisionPort System was used to complete a laparoscopic cholecystectomy for removal of a gall bladder and was performed at Lowell General Hospital in Lowell, Massachusetts by Dr. David Earle, founder of the New England Hernia Center and associate professor at Tufts University School of Medicine in Boston.

“The VisionPort system is a revolutionary product for laparoscopy that addresses many unmet needs in the operating room,” shared Dr. Earle. “I believe that the VisionPort will not only change how surgeons think about performing minimally invasive surgery but will enhance laparoscopy in both academic and austere environments. This is the first major innovation in visualization since laparoscopy first gained popularity in the early 1990s, and I’m very excited to be a part of it.”

The VisionPort System is a novel surgical imaging and access system that eliminates the need for a surgical team member to hold and manage a laparoscope and eliminates the need for a separate port in the patient. The innovative single-use VisionPort places the camera on the distal end of an access port allowing multiple advantages over existing laparoscopic systems. By combining 6 pieces of equipment needed for traditional laparoscopic surgery into two, it provides value across multiple stakeholders. The VisionPort System received FDA 510(k) clearance in June 2021.

“The New View Surgical team is excited to embark on this next step in our journey,” stated Bryce Klontz, New View Surgical President and CEO. “We are fortunate to have thought leaders like Dr. Earle partnering with us during the initial limited market release of the VisionPort System. With each additional procedure we are collecting robust clinical and economic data in support of our value proposition and learning from our partner surgeons as we refine our strategy for full commercial release in 2023.”

About New View Surgical, Inc

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that address a variety of unmet market needs The company’s proprietary VisionPort System combines multiple imaging and access devices into one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical, operational, and financial advantages to minimally invasive surgery operating rooms around the world. For more information, please visit www.newviewsurg.com .

Contacts For Press Inquiries:

New View Surgical, Inc.
info@newviewsurg.com
w w w.newviewsurg.com

New View Surgical, Inc. Closes $12.1M Series B-1 Financing

bklontz@newviewsurg.com (Bryce Klontz) — Mon, 21 Nov 2022 13:28:07 GMT

New View Surgical, Inc. Closes $12.1M Series B-1 Financing, Readies Limited Market Release of its VisionPort™ System For Minimally Invasive Surgery

November 21, 2022 10:00 AM Eastern Standard Time

BOSTON --( BUSINESS WIRE )-- New View Surgical, Inc ., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), today announced the closure of a $12.1M Series B-1 equity financing round to fund the commercialization of its VisionPort™ System. The company expects to launch the VisionPort System in the US before the end of 2022.

The VisionPort™ System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder reducing the need for a separate surgical team member to hold and manage a laparoscope. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, make state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity.

“We’re excited to bring this revolutionary technology to key hospitals and surgical teams that supports our mission to advance the growth of minimally invasive surgical procedures worldwide, holistically addressing the clinical, operational, and financial needs of the operating room,” said Bryce Klontz, President and CEO. “The funds raised in this Series B-1 round came exclusively from our current investors, a testament to our company’s accomplishments to date and vision for how we can positively impact the minimally invasive surgery space in the future.”

New View Surgical’s Chief Commercial Officer, Shane Johnson shared, “I have been fortunate to be involved with some incredible technology in my career. This is the first time that I have launched a product that adds value across all stakeholders, clinical and financial alike in such a profound way. The VisionPort System is unique in that it provides surgeons with novel viewpoints of the operative field, workflow efficiencies for staff, reduced risks to the patient, and lower costs for the facility.”

“The message from surgeons who've used the VisionPort couldn't be clearer -- the device simplifies and enhances operators' view of the surgical field,” said Dr. John Younger, a member of the New View Surgical Board and one of the deal leads for the New York Angels. “Beyond that, I think what drove investors into the deal was this: the instrument's capacity to eliminate the need for a separate team member to manage a conventional laparoscope and VisionPort's capacity to reduce capital and recurring equipment costs makes the value proposition impactfully economic for surgical practices.”

About New View Surgical, Inc.

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ System combines multiple imaging and access devices into one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical, operational, and financial advantages to minimally invasive surgery operating rooms around the world. For more information, please visit www.newviewsurg.com .

Contacts

For Press Inquiries:

New View Surgical, Inc.

info@newviewsurg.com

www.newviewsurg.com

How to Find Product-Market Fit by Going Deep Versus Wide: Medsider Interview with New View Surgical CEO Bryce Klontz

Tue, 20 Sep 2022 18:43:19 GMT

How to Find Product-Market Fit by Going Deep Versus Wide: Interview with New View Surgical CEO Bryce Klontz

September 2022

To Listen to Podcast Click Here

When Bryce Klontz started his role as CEO and President of New View Surgical six years ago, he already had two decades of medtech experience under his belt. Experience he’s since leveraged to close out a successful Series B round of financing and secure 510(k) FDA clearance.

Before joining New View, Bryce was the Vice President of Commercial Strategy and Emerging Markets for Covidien. There, he expanded the medical devices conglomerate across Asia, Africa, Latin America, and the Middle East.

Under Bryce’s leadership, New View is pioneering laparoscopic technology. Their VisionPort combines the laparoscope, camera, light, and access port into a single instrument that promises to slash the cost and preoperative time of a laparoscopy.

The device also shows the potential to reduce the number of incisions needed for some surgeries and widen access to the surgery by making laparoscopic technology easier to transport to the patient’s location.

These innovations garnered New View Surgical widespread recognition. At the Keiretsu Forum Investor Capital Expo in 2020, angel investors selected New View as the “Most Valued Company.” Funding and regulatory successes followed, with the business attracting over $14 million in total capital and securing 510(k) clearance.

In this interview, Bryce Klontz shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit.

New View Surgical, Inc. Strengthens Executive Leadership Team with Appointment of Shane Johnson as Chief Commercial Officer

Thu, 16 Jun 2022 15:09:54 GMT

New View Surgical, Inc. Strengthens Executive Leadership Team with Appointment of Shane Johnson as Chief Commercial Officer

June 16 2022

New View Surgical, Inc. Strengthens Executive Leadership Team with Appointment of Shane Johnson as Chief Commercial Officer

BOSTON--(BUSINESS WIRE)--New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today the appointment of Shane Johnson as Chief Commercial Officer. Shane will be responsible for leading the company's commercialization activities. Shane has more than 25 years of med tech commercial experience, having previously served as Vice President of Sales at Aerin Medical, Vertiflex, and Kyphon.

“We are excited to welcome Shane to New View Surgical as we look forward to launching our novel VisionPort™ System into the US market later this year,” said Bryce Klontz, Chief Executive Officer of New View Surgical. “Shane’s leadership and broad experience in launching new and innovative devices will be essential to the success of our initial market release of the VisionPort System later this year.”

Shane has a strong track record of success in the minimally invasive med tech industry, having built commercial capabilities, leading sales, operations, and marketing teams and cultivating strong key opinion leader relationships across multiple product lines and point of care environments. Of Shane’s 25 years of medical device experience, he has served the last 18 in commercial executive leadership roles. Shane joins us from Aerin Medical where he spent the last 5 years as the Vice President of Sales, creating the strategy and building the organization for the launch of two innovative products within the ENT space. Prior to Aerin Medical, Shane served as the VP of Sales at Vertiflex where he was the first commercial hire resulting in a $465M acquisition by Boston Scientific. Nearly half of his career was spent at Kyphon in progressive sales leadership roles, with his last role in the organization as a Vice President of Sales helping drive to a successful IPO and ultimately a $3.9B acquisition by Medtronic.

“New View Surgical is taking the bold step to reimagine laparoscopic visualization and create exceptional clinical and economic value,” commented Shane. “I joined New View Surgical because of the unique opportunity to redefine how minimally invasive surgery can be accomplished. It is rare to find a product that can provide increased value across multiple stakeholders including the patient, physician and site of service. The vision that CEO, Bryce Klontz and the Board has created, along with the enormous market opportunity, positions New View Surgical to drive a paradigm shift within the minimally invasive surgical space.”

The VisionPort™ System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder and allows multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, making state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity.

New View Surgical, Inc. Closes $9M Series B Financing

Wed, 03 Nov 2021 01:22:33 GMT

New View Surgical, Inc. Closes $9M Series B Financing to Fund Initial Market Release of its VisionPort™ System for Minimally Invasive Surgery

NEWS RELEASE

BOSTON, MA, November 2, 2021. New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced that it raised $9M in a Series B financing round to fund the initial market release of its VisionPort™ System. The Series B financing follows the company’s announcement of FDA clearance for its VisionPort System platform in June of this year. The round was led by members of New York Angels with Corza Medical, Inc., IAG Capital Partners, Charleston Angels Partners, Ariel Savannah Angel Partners, Keiretsu Forum, Mid Atlantic Bio Angels (MABA) and SSIP, among others participating in the round.

Commenting on the close of the Series B round, Bryce Klontz, President & CEO, said, “We’re excited to bring this revolutionary technology to key hospitals and surgical teams that supports our mission to advance the growth of minimally invasive surgical procedures worldwide and holistically address the clinical, operational, and financial needs of the operating room. A majority of funds raised in this round resulted from follow-on investments from current investors, which is a testament to our company’s vision and accomplishments to date.”

In conjunction with this fundraise, the New View Surgical Board of Directors will expand to include John Younger, M.D., a member of New York Angels and Tom Testa, Chief Financial Officer at Corza Medical, Inc. Dr. Younger and Mr. Testa will serve alongside current board members, Chairman, Scott Flora, Melvin Prenovitz, Nancy Briefs, Mark Schneider and Bryce Klontz, President & CEO.

“New View Surgical is taking the bold step to reimagine laparoscopic visualization,” commented John Younger, M.D, Managing Director at ArgoPond, a life science advisory and capital firm based in Philadelphia. “The company’s game-changing visualization technology will enable less invasive surgery for patients and will make state-of-the-art visualization more accessible to surgeons, regardless of setting. Multiple members of New York Angels participated in this round and are excited about what the future holds for New View Surgical and the VisionPort System platform.” Added Tom Testa, Chief Financial Officer of Corza Medical, Inc., “New View Surgical is taking a holistic approach to adding value and is setting the stage for improved clinical care and operational efficiencies, all while lowering costs.” Commenting on the new Board appointments, Klontz said “We are pleased to welcome John and Tom to the Board, and we are excited to welcome several new investors to the New View Surgical family.”

The VisionPort™ System is a novel surgical imaging and access system that simplifies laparoscopic procedures by reducing the need for a separate camera port and camera holder and allows multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, making state-of-the-art technology more accessible. The VisionPort System is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities and is adaptable to a wide variety of surgical environments, representing a significant market opportunity.

About New View Surgical, Inc.

Medtech Money Episode 4: CEO Explains Raising Early Stage Capital - Bryce Klontz, CEO at New View Surgical

Thu, 15 Jul 2021 01:04:18 GMT

In this episode, Giovanni and Bryce discuss raising capital from angel groups, the differences between angels and VCs, east vs. west coast investors and more.

The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.

New View Surgical, Inc. Announces FDA Clearance of its VisionPort™ System for Minimally Invasive Surgery

Wed, 23 Jun 2021 15:14:36 GMT

New View Surgical, Inc. Announces FDA Clearance of its VisionPort™ System for Minimally Invasive Surgery

June 23, 2021

The VisionPort™ is the first surgeon-controlled, multi-camera laparoscopic visualization system

BOSTON--(BUSINESS WIRE)--New View Surgical, Inc., a medical device company developing proprietary imaging and access technologies for minimally invasive surgery (MIS), announced today that it received 510(k) clearance from the U.S. Food and Drug Administration for its VisionPort™ System. The VisionPort™ imaging and access system simplifies laparoscopic procedures for hospitals and provides surgeon-controlled visualization. Its dual-camera design offers multiple, simultaneous views of the anatomy and surgical instrumentation – unavailable with conventional laparoscopic systems. The VisionPort puts the most advanced visualization technology more readily in the hands of customers and is intended to be used in a broad range of diagnostic and therapeutic procedures within the thoracic and abdominal cavities. It is adaptable to a wide variety of surgical environments, representing a significant market opportunity.

“The VisionPort System allows the surgeon to control the scope and keeps the tip of the instruments within the field of view at all times. This has significant potential to make the operation easier for the surgeon and reduce risk to the patient,” commented David Earle, MD, FACS, Director of the New England Hernia Center and Associate Professor of Surgery at Tufts University School of Medicine in Boston, MA. “Additionally, the VisionPort provides multiple, simultaneous views of the operative field. Previously, changing the viewing angle was only possible by removing the laparoscope and moving it to another port, frequently wasting time and causing frustration. Furthermore, the VisionPort eliminates a separate incision and the need for a surgical assistant to hold the scope. The elimination of the camera port and assistant means surgeons and hospitals can expand access to the operating room without increasing staffing requirements. This increased efficiency is good for the surgeon, the facility, and most importantly, the patient.”

Added Dr. Earle, “It’s been exciting to collaborate with the New View Surgical team during the development of the VisionPort. Not only will this technology allow more patients to access minimally invasive surgical techniques, it will also make many high volume procedures easier for surgeons to perform.”

“FDA clearance of the VisionPort is a significant milestone for New View Surgical. We’re excited to bring a revolutionary technology to market that supports our overall mission to improve the outcomes and efficiency of laparoscopic surgical procedures, all while increasing patient access to minimally invasive surgical techniques worldwide,” said Bryce Klontz, President & CEO. “The FDA clearance process for the VisionPort was completed in less than 90 days. We are incredibly pleased with the timeline as we can now move ahead with the next stages of company development and commercialize this exciting technology.”

New View Surgical, Inc. is a medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ System combines multiple imaging and access devices into one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.

New View Surgical, Inc. Recognized as ‘Most Valued Company’ at Keiretsu Forum Investor Capital Expo

Thu, 17 Dec 2020 16:17:35 GMT

New View Surgical, Inc. Recognized as ‘Most Valued Company’ at virtual Keiretsu Forum Investor Capital Expo

December 17, 2020

Hand-picked by hundreds of attending angel investors as a stand-out innovator amongst group of highly touted, growth-stage entrepreneurial companies from U.S. and Canada

SEATTLE, WA—New View Surgical, Inc. an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, was recognized as one of the top three ‘Most Valued Company’ at the Keiretsu Forum Investor Capital Expo that is showcasing 36 late-stage growth companies seeking funding. Nearly 50 angel groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors have attended the first two sessions of the Expo.

The Investor Capital Expo is hosted by Keiretsu Forum, the world’s largest angel investor network ranked by Pitchbook #1 in two categories: “Most active investors early stage” and “Most active investors late stage.”

New View Surgical was hand-picked by hundreds of attending angel investors as a stand-out innovator amongst a group of highly touted, entrepreneurial companies from U.S. and Canada. The final Investor Capital Expo Session 3 is on November 11th.

"We are very pleased to have been selected as a Most Valued Company by this experienced and active group of early stage investors," said Bryce Klontz, President & Chief Executive Officer at New View Surgical. “We appreciate the support of the Keiretsu Forum members and congratulate everyone involved with the Investor Capital Expo. Nearing the completion of a Series A-1 financing, New View Surgical is leveraging investor capital to bring our VisionPort System surgical technology to market. Our novel VisionPort System supports our overall mission to decrease cost, improve surgical imaging and increase access to minimally invasive surgical procedures for patients around the world.”

New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. VisionPort™ combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.

Keiretsu Forum also named Caleb Carr, CEO of Vita Inclinata Technologies, as its “Entrepreneur of the Year” award; and also named member Arthur Goldman as its “Most Valued Investor” award winner.

About Keiretsu Forum

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors. Keiretsu Forum was founded in 2000 by Randy Williams. Keiretsu Forum today is a worldwide network of capital, resources and deal flow with over 50 chapters on three continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities. The community is strengthened through its involvement in social and charitable activities.

New View Surgical, Inc. Closes Series A Round of Financing

Mon, 17 Jun 2019 15:22:40 GMT

New View Surgical, Inc. Closes Series A Round of Financing

June 17, 2019

New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million. The financing was over-subscribed due to investor demand. New View Surgical will deploy the financing to complete the development of its VisionPort™ System, expand the company’s intellectual property portfolio and submit a 510(k) U.S. Food and Drug Administration (FDA) filing.

"We are very pleased to have closed our Series A financing and are encouraged by the confidence shown by our investors, including individual members from New York Angels, Mid-Atlantic Bio-Angels, Keiretsu Forum and Ariel Southeast Angel Partners, among others," said Bryce Klontz, President & Chief Executive Officer at New View Surgical. “Most importantly, we’re leveraging this capital to bring a surgical technology to market that supports our overall mission to decrease cost, improve surgical imaging and increase access to minimally invasive surgical procedures for patients around the world.”

“I am very excited about the efficiency and progress made by the team at New View Surgical,” said David Earle, MD, FACS, Director of the New England Hernia Center, Associate Professor of Surgery at Tufts University School of Medicine, and Scientific Advisory Board member of New View Surgical. “Not only will this technology allow more patients to access minimally invasive surgical techniques, it will make many high-volume cases easier for surgeons to perform.”

New View Surgical’s initial device, the VisionPort™ System, is a novel surgical imaging and access system for minimally invasive surgery that aims to simplify laparoscopic procedures across all specialties by reducing the need for a separate camera port and camera holder and allowing multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, allow access to the latest in surgical techniques where it is currently unavailable. Dr. Earle stated, “the VisionPort™ System allows the surgeon to control the scope and keeps the tip of the instruments within the field of view at all times. This has significant potential to make the operation easier for the surgeon and may reduce risk to the patient as well. Furthermore, having multiple simultaneous views of the operative field allows for different viewing angles that were previously possible only by removing the scope and moving it to another port. Moving the scope frequently smudges the scope, creates condensation on the lens, causes frustration and wastes time. The elimination of the camera port and an assistant to hold the scope means surgeons and hospitals can be more efficient by accommodating more procedures, which is good for the surgeon, the facility, and most importantly, the patient.”

About New View Surgical, Inc. New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.

Mid Atlantic Bio Angels Invests in New View Surgical

Fri, 10 Nov 2017 16:26:15 GMT

Mid Atlantic Bio Angels Invests in New View Surgical

November 2017

NEW YORK, Nov. 10, 2017 -- Mid Atlantic Bio Angels (MABA) announces today that it has made an investment in Boston-based New View Surgical., which has developed a proprietary surgical imaging system for laproscopic surgery. This is the eighth investment made by MABA since its founding.

“Laproscopic and minimally invasive surgeries have become the norm, and it is important that physicians have the most updated technology to both improve outcomes through enhanced control, while hospitals are given the opportunity to continue to minimize costs,” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting. “We have been impressed with New View Surgical’s technology and management, and believe they offer solutions that will help bring laproscopic surgeries to the next level.”

New View Surgical is an early-stage surgical visualization company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging system for minimally invasive surgery. The company’s proprietary VisionPort™ system combines four instruments into one and is being developed as a disposable device. It enters as a trocar, functions as a laparoscope and deploys as a camera and an instrument channel. The key advantage of VisionPort over current visualization systems is that, for the first time, it gives the primary surgeon total control of both the instruments and visualization. The system provides a full, straight-on view of the tissue and instrument tips at all times, limiting accidental injury to adjacent organs as well as lowering the surgeon’s skill threshold and ergonomic stress. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.

“The New View Surgical team is very pleased to have multiple MABA members participate in our Series A round. The investments from MABA support the further development of our VisionPort™ System and our team’s mission to improve the safety, efficiency and cost profile of today’s surgical visualization equipment,” said Bryce Klontz, president and CEO of New View Surgical. “The memberships’ overall focus on the life-sciences also offers us a strong group of sophisticated investors with whom our team can network throughout the critical months ahead.”

About Mid Atlantic Bio Angels Mid Atlantic Bio Angels ( http://bioangels.net ) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.

New View Surgical, Inc. to Present at Emerging Technology Summit in San Francisco

Wed, 09 Nov 2016 16:29:39 GMT

New View Surgical, Inc. to Present at Emerging Technology Summit in San Francisco

May 2016

New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that it has been selected as a Presenting Company at the upcoming 2016 Emerging Medical Technology Summit to be held in San Francisco, November 9-11, 2016. The prestigious EMT Summit is co-hosted by Life Science Intelligence and The MedTech Strategist and will feature presentations by CEOs of 70 hand-picked early-stage medical device companies from around the world raising capital and/or seeking quality strategic partners.

New View Surgical, Inc. Selected for MassChallenge 2016 Accelerator - Joins 128 startups from around the world

Thu, 19 May 2016 15:28:04 GMT

New View Surgical, Inc. Selected for MassChallenge 2016 Accelerator - Joins 128 startups from around the world for 4-month program in Boston

May 19, 2016

BOSTON, May 19, 2016 – Today New View Surgical, Inc. announced it will join MassChallenge Boston , the most startup-friendly accelerator on the planet. One of 128 startups participating, New View Surgical, Inc. will benefit from mentorship, office space, and a vast network of experienced entrepreneurs, corporate partners, and investors. In November, all MassChallenge Boston startups will compete for $1.5M total in cash awards with no equity taken.

“The team at New View Surgical, Inc. is extremely proud of being selected as a Finalist from over 1,700 applicants for the MassChallenge 2016 Accelerator. We fully expect that the extensive network of entrepreneurs, business partners and investors associated with MassChallenge will help propel New View Surgical toward achieving our goal of commercializing the VisionPort™, our novel, game-changing surgical imaging technology that aims to redefine and simplify laparoscopic surgery”, commented Bryce Klontz, New View Surgical’s President and CEO.

“We received consistent feedback from our judges about the quality of applicants this year, and I'm confident we’ll have an incredibly high-caliber class of entrepreneurs joining us in Boston," added MassChallenge Boston Managing Director Scott Bailey. "These entrepreneurs will be challenged throughout the program to impact communities and provide disruptive solutions across a wide range of industries. Be on the lookout for them this summer!”

This year’s MassChallenge Boston class was selected from more than 1,700 applicants across a diverse range of industries and geographies, including 65 countries and 37 states. The accelerator program will culminate on November 2, 2016, at the MassChallenge Boston Awards Ceremony, where entrepreneurs will pitch their startups with the chance to win a share of $1.5 million in zero-equity awards.

New View Surgical, Inc. Names Bryce Klontz as President & CEO

Mon, 01 Feb 2016 16:31:15 GMT

New View Surgical, Inc. Names Bryce Klontz as President & CEO

February 2016

New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that it has named Bryce Klontz as President &CEO, effective immediately. Mr. Klontz is an accomplished global sales and marketing executive, having built and led commercial teams in the US, Europe and Asia. Most recently, Mr. Klontz was the Vice President of Commercial Strategy, Emerging Markets at Covidien, PLC where he led efforts to build commercial capabilities within the $1.5B+ Asia, Latin America, Emerging Europe, Middle East and Africa geographies. Mr. Klontz spent 14 years at Covidien in various leadership roles including Marketing Director in both the US and Europe, as well as 3 years as Vice President, Surgical Devices Business Unit, in Asia. Mr. Klontz also served as the global post-M&A integration lead for two of Covidien's most impactful acquisitions. Earlier in his career, Mr. Klontz played a pivotal role in the global launch of The CO2 Heart Laser System. Mr. Klontz received his MBA in marketing and finance from Carroll School of Management at Boston College and a Bachelor's degree from Northwestern University.

New View Surgical, Inc. Announces U.S. Patent for VisionPort™ Technology

Fri, 05 Sep 2014 15:32:34 GMT

New View Surgical, Inc. Announces U.S. Patent for VisionPort™ Technology

September 2014

New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that the U.S. Patent and Trademark Office has issued a patent for the design behind the company’s entry device, the VisionPort™. The recently-issued patent (U.S. Patent Number 8,834,358 B2) is an extension of the Company’s initial patent (US Patent# 8,439,830 B2) issued in May 14, 2014 and was issued for a cannula-based system with an integrated camera and illumination. With this exclusive technology, visualization of the operative field is under the direct control of the primary surgeon through each one of his or her access ports, improving surgical outcomes and procedural efficiency.

new-view-surgical

New View Surgical is proud to be recognized as one of the Top 10 Companies to Watch in 2023 by Medtech Outlook Magazine

New View Surgical is proud to be recognized as one of the Top 10 Companies to Watch in 2023 by Medtech Outlook Magazine

New View Surgical Announces First Commercial Case

New View Surgical Announces First Commercial Case of the VisionPort™ System, Performed by David Earle, M.D., F.A.C.S.

New View Surgical, Inc. Closes $12.1M Series B-1 Financing

How to Find Product-Market Fit by Going Deep Versus Wide: Medsider Interview with New View Surgical CEO Bryce Klontz

How to Find Product-Market Fit by Going Deep Versus Wide: Interview with New View Surgical CEO Bryce Klontz

New View Surgical, Inc. Strengthens Executive Leadership Team with Appointment of Shane Johnson as Chief Commercial Officer

New View Surgical, Inc. Strengthens Executive Leadership Team with Appointment of Shane Johnson as Chief Commercial Officer

New View Surgical, Inc. Closes $9M Series B Financing

New View Surgical, Inc. Closes $9M Series B Financing to Fund Initial Market Release of its VisionPort™ System for Minimally Invasive Surgery

Medtech Money Episode 4: CEO Explains Raising Early Stage Capital - Bryce Klontz, CEO at New View Surgical

In this episode, Giovanni and Bryce discuss raising capital from angel groups, the differences between angels and VCs, east vs. west coast investors and more.

New View Surgical, Inc. Announces FDA Clearance of its VisionPort™ System for Minimally Invasive Surgery

New View Surgical, Inc. Announces FDA Clearance of its VisionPort™ System for Minimally Invasive Surgery ﻿

New View Surgical, Inc. Recognized as ‘Most Valued Company’ at Keiretsu Forum Investor Capital Expo

New View Surgical, Inc. Recognized as ‘Most Valued Company’ at virtual Keiretsu Forum Investor Capital Expo

New View Surgical, Inc. Closes Series A Round of Financing

New View Surgical, Inc. Closes Series A Round of Financing

Mid Atlantic Bio Angels Invests in New View Surgical

Mid Atlantic Bio Angels Invests in New View Surgical

New View Surgical, Inc. to Present at Emerging Technology Summit in San Francisco

New View Surgical, Inc. to Present at Emerging Technology Summit in San Francisco

New View Surgical, Inc. Selected for MassChallenge 2016 Accelerator - Joins 128 startups from around the world

New View Surgical, Inc. Selected for MassChallenge 2016 Accelerator - Joins 128 startups from around the world for 4-month program in Boston

New View Surgical, Inc. Names Bryce Klontz as President & CEO

New View Surgical, Inc. Names Bryce Klontz as President & CEO

New View Surgical, Inc. Announces U.S. Patent for VisionPort™ Technology

New View Surgical, Inc. Announces U.S. Patent for VisionPort™ Technology

New View Surgical, Inc. Announces FDA Clearance of its VisionPort™ System for Minimally Invasive Surgery